Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067
Maganizo Chagomerana(University of North Carolina at Chapel Hill), Mina C. Hosseinipour, Thomas Campbell(University of Colorado Anschutz Medical Campus), Deborah Langat(Kenya Medical Research Institute), Carlee Moser(Harvard University), Henriette Burger(Stellenbosch University), Margaret Borok(University of Zimbabwe), Wadzanai Samaneka(University of Zimbabwe), Naftali Busakhala(Moi University), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Brenda Hoagland(Fundação Oswaldo Cruz), Triin Umbleja(Harvard University), McNeil Ngongondo, Noluthando Mwelase(University of the Witwatersrand), Mulinda Nyirenda(University of Malawi), Rosie Mngqibisa, Minhee Kang(Cancer Research And Biostatistics), Michael D. Hughes(Virginia Tech), Evangeline Njiru(Moi University)
Cited by 0
Related Papers
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
|New England Journal of Medicine|2021|548
Alterations in the Gut Microbiota Associated with HIV-1 Infection
|Cell Host & Microbe|2013|508